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One hundred twenty-one adult liver transplant recipients were studied for the incidence, 
risk factors, and morbidity associated with herpesviruses infections after transplantation. 
The overall incidence of infection was 59070 for cytomegalovirus (CMV), 35070 for herpes 
simplex virus (HSV), 25070 for Epstein-Barr virus (EBV), and 7070 for varicella-zoster vi-
rus (VZV). Primary CMV infection occurred in 46070 and reactivation CMV infection 
in 67070 of the susceptible recipients. Symptomatic and disseminated CMV diseases were 
more common when patients developed primary infection (P < .01, for both compari-
sons). The donor organ appeared to be the only important source of CMV infection in 
seronegative recipients. The use of OKT3 antibodies was associated with disseminated 
CMV disease in patients with primary infection (P = .04) but not with reactivation infec-
tion (P > .10). Although most HSV infections were oral or genital reactivations, three 
cases of HSV hepatitis occurred - one was a primary infection. Symptomatic reactiva-
tions of HSV were observed in 531170 of HSV-seropositive recipients who received OKT3, 
versus 31070 of seropositive recipients who did not receive OKT3 (P = .05). 
Infections with cytomegalovirus (CMV) and other 
herpesviruses are a major source of morbidity and 
mortality after organ transplantation [1]. Of all the 
herpesviruses, CMV is the agent most often as-
sociated with severe disease or death [2]. A number 
of factors contribute to the severity of CMv infec-
tion in transplant recipients. Primary infection as op-
posed to reactivation infection with the virus [2, 3] 
and the use of immunosuppressive regimens contain-
ing anti-thymocyte globulin (ATG) appear to be as-
sociated with more-severe CMV disease [4, 5]. In ad-
dition, the type of transplant operation is an 
important determinant of the morbidity due to 
CMV. For instance, both bone marrow and heart-
lung transplant recipients have higher rates of CMV 
pneumonia than do kidney recipients [1, 6, 7]. 
Our earlier studies of infections in kidney, heart, 
heart-lung, and liver transplant recipients in Pitts-
burgh showed that CMV and other herpesviruses 
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were a significant problem in liver transplant 
recipients receiving cyclosporine [8]. A study of vi-
ral infections, incuding herpesvirus infections, in 
pedia.tric transplant recipients, most of whom were 
liver recipients, has recently appeared [9], but there 
still has been no comprehensive study of herpesvi-
rus infections in adult liver transplant recipients, par-
ticularly since the initiation of routine cyclosporine 
monitoring in 1983. ;rherefore, we studied 121 con-
secutive adult liver transplant recipients at our 
institution to analyze the incidence, timing, risk fac-
tors, and clinical outcome associated with herpes-
viruses infections. We hoped to determine whether 
the hepatic allograft was a significant source of CMV 
infection and whether the use of newer immunosup-
pressive measures, such as OKT3 monoclonal anti-
body (Ortho Pharmaceutical, Raritan, NJ) intro-
duced for treating liver rejection, had a measurable 
impact on CMV or herpes simplex virus (HSV) in-
fection. 
Patients and Methods 
Study population. The study population con-
sisted of 121 consecutive adults who underwent or-
thotopic liver transplantation at our institution be-
tween January 1984 and September 1985, who 
survived for at least 72 h postoperatively, and on 
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Herpesviruses and Liver Transplantation 
whom preoperative serum samples were available. 
There were 46 men and 75 women whose average ages 
were 38 and 39 y, respectively. Their clinical diag-
noses were primary biliary cirrhosis (35), chronic ac-
tive hepatitis (24), sclerosing cholangitis (20), cryp-
togenic cirrhosis (10), malignancy (9), CaroIi's 
diseases (3), drug- or alcohol-induced hepatic 
necrosis (5), hemochromatosis (3), Budd-Chiari syn-
drome (3), a-I-antitrypsin deficiency (2), Wilson's 
disease (2), secondary biliary cirrhosis (4), and cys-
tic fibrosis (1). There were a total of 26 deaths. The 
duration of follow-up in living patients ranged from 
313 to 930 d, with a median of 530 d. Clinical data 
regarding infections were collected by reviewing pa-
tients' records as well as by follow-up by two of the 
authors (N. S. and S. K.). 
Immunosuppression. Standard postoperative 
immunosuppression consisted of cyclosporine (CsA) 
and corticosteroids. CsA was administered iv at a 
dose of 2 mg/kg per d on the day of surgery and 
then orally at 6 mg/kg per d after surgery. The dos-
age was adjusted individually to achieve a whole 
blood level of CsA between 800 and 1000 ng/mL, 
as measured by RIA. Beginning on the day of sur-
gery, methylprednisolone was administered iv at a 
dose of 200 mg and tapered over five to seven days 
to a maintenance dose of 20 mg of methylpredniso-
lone or oral prednisone. Rejectioll episodes were 
treated either with a "recycling" of high-dose oral 
steroids starting at 200 mg of prednisone and taper-
ing to 20 mg over five days or with l-g iv boluses 
of methylprednisolone. For the purpose of this study, 
one recycle and one bolus of steroids were consid-
ered equivalent. For more-severe degrees of rejection, 
OKT3 antibody was administered. Azathioprine 
(AZA) was usually added to the immunosuppres-
sive regimen to reduce CsA dosage in patients ex-
periencing nephrotoxicity. AZA was administered 
orally at a dose of 1-2 mg/kg, and OKT3 was ad-
ministered iv at a dose of 5 mL daily and continued 
for seven to 14 days. Mean monthly CsA levels for 
the first three months postoperatively were deter-
mined from the monthly means of each patient's 
weekly median levels of CsA. 
Laboratory follow-up. Preoperative serum sam-
ples from all transplant recipients were analyzed for 
antibodies to CMV, Epstein-Barr virus (EBV), and 
HSV. A semiautomated immunofluorescent test 
(FIAX®; International Diagnostic Technology, San 
Jose, Calif) was used for testing antibodies to CMV 
and HSV, and titers of ~PM and ~fOI respectively, 
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were considered positive. All equivocal CMV FlAX 
results were checked with an anticomplement immu-
nofluorescence test (ACIF), and titers of ;:, 1:4 were 
considered positive [10]. Ordinarily, a positive 
postoperative culture for CMV was considered ade-
quate for diagnosing CMV infection [2, 11]. In the 
absence of positive CMV cultures, postoperative sera 
were also assayed for CMV antibodies by ACIF. An-
tibodies to EBV viral capsid antigen (VCA) and early 
antigen (EA) were determined on preoperative and 
postoperative sera by standard immunofluorescence, 
and titers ~1:R were considered positive [12]. Sig-
nificant antibody rises (greater than fourfold) were 
were confirmed by simultaneous assay. In addition, 
throat washes and urine and buffy coat samples were 
obtained from recipients every two to four weeks 
postoperatively and cultured for CMV [8]. 
One patient with no detectable HSV antibodies 
before transplantation developed HSV hepatitis af-
ter transplantation. Serum samples from this recip-
ient and donor were analyzed for HSV type-specific 
antibodies by an immunodot enzymatic assay [13, 
14]. Briefly, HSV type I-specific glycoprotein (gG-
1) and HSV type 2-specific glycoprotein (gG-2) were 
prepared as described by Lee et al. [13, 14] and used 
as antigen in an immunodot assay on small disks of 
nitrocellulose membrane in 96-well plates. The sera 
were tested at a 1 :50 dilution, and serum controls 
were used for each assay. 
CMV infection and disease. Primary infection 
was defined by isolation of virus or by seroconver-
sion in a patient who was seronegative before trans-
plant surgery. Reactivation infection was diagnosed 
by either a fourfold or greater rise in antibody titers 
compared withpretransplant levels by ACIF or by 
isolation of virus in a seropositive recipient. Twenty-
eight patients did not have postoperative CMV cul-
tures or sera available for antibodies testing and were 
therefore excluded from analysis of CMV infections; 
93 patients then remained for evaluation. To exclude 
the effect of passively transferred antibodies from 
blood transfusion during surgery, we only used sera 
collected >30 d after transplantation to document 
rises in antibody titer. Clinical diseases caused by 
CMV infection were the following types: viral syn-
drome, localized CMV disease, and disseminated 
CMV disease. Viral syndrome due to CMV required 
the following: (1) laboratory evidence of CMV in-
fection, as defined above; (2) fever ~PU C for at least 
one week and no other source to account for it; and 
(3) one of the following findings - atypicallympho-
--"~"""-~"--Di •• -Kgt~· a. ____________________ ....................... ..... 
. ,______ ._ _ '·I:i, _~~ ~DID~KlDI; D;D;D:>l~I~ 
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cytes ~PMTM; white blood cell count «4000/mmJ ; and 
platelets «100 OOO/mmJ • Localized CMV disease 
was defined as tissue invasion of a single organ de-
termined histopathologically and/or by culture of 
virus from tissue. Disseminated CMV disease was 
defined as tissue involvement of two or more non-
contiguous sites. 
EBV infection. EBV infection was defined by a 
fourfold or greater rise in IgG antibody titers against 
VCA occurring> 30 d after transplantation. Thirty-
four of 121 patients were excluded from analysis of 
EBV infection because of a lack of appropriate post-
operative sera, and 87 assessable patients then re-
mained. Patients were defined as having a symptom-
atic EBV infection if they had either a febrile viral 
syndrome defined the same way as for CMV, but 
with no laboratory evidence of CMV infection, and 
a fourfold or greater rise in IgG VCA titers to EBY. 
We defined EBV-associated lymphoproliferative le-
sions by the presence of EBV DNA in tissues by using 
nucleic acid hybridization and/or by the presence of 
EBV nuclear antigen by using immunofluorescent 
staining [12]. 
HS Vand VZ V infections. HSV infection was de-
fined as the presence of typical symptomatic oral or 
genital ulcers. For atypical lesions or those outside 
the genital or oral area, isolation of virus or typical 
viral cytopathology was also required. 
VZV infection was determined clinically by the 
presence of typical dermatomallesions. In one pa-
tient with clinical varicella the virus was cultured 
from skin lesions and blood, and the patient's 
pretransplant serological status was determined by 
an indirect fluorescent-antibody test (Electro-
Nucleonics, Columbia, Mass). 
Statistical methods. Observed proportions were 
compared using the "x.z test or, if the numbers were 
small, Fisher's two-tailed exact test. Calculated 
Singh el al. 
means were compared using Student's t test. Differ-
ences were considered significant at P < .05. 
Results 
CMV infection. Fifty-five (59070) of 93 patients 
developed CMV infection. These included 17 (46070) 
of 37 seronegative recipients and 38 (67070) of 56 
seropositive patients (table I). Fifteen (88070) of 17 
recipients with primary infection had symptomatic 
disease. Seven patients had a viral syndrome, three 
patients had localized CMV infection, and five pa-
tients had disseminated CMV infection. Two cases 
of localized CMV involved the lung, and one in-
volved the small bowel. In the latter case, the diag-
nosis was made by endoscopic biopsy through an 
ileostomy. Of the five patients with disseminated 
CMV, three died, and multiple organ involvement 
was found at autopsy. Two patients with dissemi-
nated CMV disease (one with hepatitis and pneu-
monitis and the other with hepatitis and duodeni-
tis) recovered. 
Symptomatic CMV disease was diagnosed in 12 
(32070) of 38 patients with reactivated CMV infec-
tion and was significantly less frequent than after 
primary infection (P < .01). Nine patients had a be-
nign viral syndrome, two patients had localized CMV 
infection (one with hepatitis and one with pneumo-
nitis), and one patient had disseminated CMV. Dis-
seminated CMV infection occurred less often in pa-
tients with reactivation infection (one of 38) 
compared with patients with primary CMV infec-
tion (five of 17; P < .01). 
Mortality. Of the 55 infected patients, 12 (22070) 
died. This rate was higher than, but not significantly 
different from, the 8070 (three of 38) mortality rate 
found in uninfected patients (P = .12). Also, mor-
tality in patients with symptomatic CMV infection 
Table 1. Frequency of CMV infection and symptomatic disease in liver transplant recipients. 
Preop CMV 
serology 
Negative 
Positive 
Total 
No. of 
assessable 
patients 
37 
56 
93 
NOTE. Preop = preoperative . 
Infection (070) 
17 (46) 
38 (67) 
55 (59) 
No. of patients with 
Total no. 
Viral Localized Disseminated of symptomatic 
syndrome CMV CMV patients (070) 
7 3 5' 15* (88) 
9 2 I' 12* (32) 
16 5 6 27 (49) 
• P < .01 for patients with primary infection compared with patients with reactivation infection who developed symptomatic 
CMV disease and with patients with disseminated CMV disease (P < .01 for both comparisons). 
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Table 2. Relation of CMV infection to blood products transfused. 
Seronegative recipients· Seropositive recipients· 
Blood product 
(mean units 
transfused) 
Primary infection Not infected Reactivation infection 
(n = 38) 
Not infected 
(n = 18) (n = 17) (n = 20) 
Red blood cells 
Fresh frozen plasma 
Cryoprecipitate 
Platelets 
Total units 
• 
29 
32 
16 
44 
121 
26 
33 
9 
32 
100 
45 
52 
13 
61 
171 
27 
34 
14 
34 
109 
.No significant differences were found between the number of units of red blood cells, fresh frozen plasma, cryoprecipitate, 
platelets, or total blood product units for infected vs. uninfected patients (P> .1). 
was 18% (five of 27) and did not differ from the 25% 
(seven of 28) mortality rate found in patients with-
out symptomatic CMV infection. The mortality rate 
was, however, 66% (four of six) for patients with dis-
seminated CMV, a rate that was significantly higher 
than the 16% (eight of 49) mortality seen in patients 
without disseminated CMV infection (P< .05). The 
excess mortality in patients with disseminated CMV 
may not be attributable solely to CMV, because all 
these patients had other bacterial or fungal infec-
tions that may also have played a role in their deaths. 
Transmission. Organ allografts have been shown 
to transmit CMV to seronegative kidney and )leart 
allograft recipients [11, 15]. The association between 
receiving a liver from a donor positive for CMV anti-
bodies and subsequent development of CMV infection 
was analyzed. Thirteen (92%) of 14 seronegative 
recipients who received livers from CMV-seropositive 
donors had evidence of CMV infection after trans-
plantation, whereas only one (8%) of 12 seronega-
tive recipients who received a liver from a CMV-
seronegative donor developed CMV infection. This 
difference in infection rate was highly significant 
. (P < .001). 
No definite relation was found between the oc-
currence of CMV reactivation infection and the 
CMV serological status of the donor. Fifteen (71%) 
of 21 seropositive patients who received a liver from 
a CMV-seropositive donor underwent CMV reacti-
vation infection; by comparison, 11 (78%) of 14 pa-
tients who were seropositive for CMV antibody be-
fore transplantation and who received a liver from 
a CMV-seronegative donor also became infected af-
ter transplantation (P > .5). This analysis suggests 
that, as in the case of renal transplant recipients, the 
organ allograft is not usually responsible for CMV 
infection in seropositive recipients [11]. All patients 
received random blood products that were neither 
tested nor selected for CMV antibody. 
The impact of transfusions and blood products 
on CMV infection in seronegative and seropositive 
recipients was also investigated. The mean number 
of units of red blood cells, fresh frozen plasma, 
cryoprecipitate, platelets, or total units of blood 
products received by infected and uninfected pa-
tients, whether they were seropositive or seronega-
tive before transplantation, was not significantly 
different. These data are shown in table 2. 
CMV injection and immunosuppression. Table 
3 shows data on the relation of symptomatic CMV 
disease and the use of additional immunosuppres-
sive agents such as OKT3, AZA, or steroids. Thir-
teen (40070) of 32 patients in the OKT3 group devel-
oped symptomatic CMV infection; this finding did 
not differ significantly from the 63% (14 of 22) rate 
of symptomatic disease in patients who received 
other immunosuppressive regimens. There was a 
trend toward more disseminated CMV infections in 
patients who received OKT3 (six [18%] of 32 vs. 0 
[0%] of 23, P = .06). Analysis of these data showed 
that patients with primary infection who received 
OKT3 had a 55% (five of nine) rate of dissemina-
tion as compared with no episodes of disseminated 
disease in the eight patients with primary infection 
who did not receive OKT3 (P = .04). There was no 
apparent effect of OKT3 on dissemination in CMV 
reactivation infection (0 of 15 vs. 1 of 23, P> .1). 
HSV injection. Of 121 patients, 95 (78%) were 
seropositive and 26 (22%) were seronegative for an-
tibodies to HSV before transplantation. All but one 
of the infections caused by HSV occurred in 
seropositive recipients and were thought to be due 
to reactivation of latent virus. Of 95 seropositive 
recipients, 39 (41 %) developed typical mucocutane-
l 
--,----------------------------
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Table 3. Relation between additional immunosuppression and symptomatic CMV infection. 
Total no. of 
No. of patients with 
Additional assessable Symptomatic Viral Localized Disseminated 
immunosuppression patients Infection infection syndrome CMV infection CMV infection 
OKT3* 53 32 13 7 0 6t 
AZA only 6 2 2 2 0 0 
Steroids only 33 20 12 7 5 0 
None I 0 0 0 0 
Total 93 55 27 16 5 6 
• All patients treated with OKT3 received additional steroids; 17 of 32 infected patients also received AZA (azathioprine). 
t p = .06 for pa,tients with disseminated CMV disease treated with OKT3 (6 of 32) vs. patients who did not receive OKTJ (0 of 23). 
ous HSV lesions, including 29 patients with oral HSV 
and 10 with genital HSV infections. Two patients de-
veloped HSV esophagitis, and two had HSV hepa-
titis without mucocutaneous lesions. The two cases 
of hepatitis were discovered at autopsy 21 and 46 d 
after transplantation. One patient had isolated HSV 
hepatitis. In the other patient, HSV hepatitis was 
part of a disseminated visceral HSV infection involv-
ing the liver, lungs, colon, and larynx. 
Only one of 26 seronegative recipients had primary 
HSV infection. She developed HSV hepatitis 21 d 
after transplantation; this finding was documented 
histopathologically by liver biopsy. HSV was also 
cultured from a bronchoalveolar lavage specimen. 
The patient received a liver from a donor seroposi-
tive for antibodies to HSV type 2 and developed an-
tibodies to HSV type 2 after transplantation. She 
was treated with iv acyclovir, and her resolution of 
HSV hepatitis was documented by falls in transam-
inase levels and by subsequent liver biopsies. 
The oral and genital HSV infections in these pa-
tients occurred a median of 19 and 24 d postopera-
tively, respectively. We did not document HSV vire-
mia or CNS infection from HSV in any patient. 
Table 4 analyzes the impact of immunosuppres-
sion on HSV infections in seropositive recipients. The 
group treated with OKT3 had more symptomatic ill-
ness due to HSV (29 [53070 1 of 54), as compared with 
patients who did not receive OKT3 (13 [31 % 1 of 41, 
P = .05). 
EBV infections. Eighty-five of 119 seropositive 
recipients were assessable for EBV infection, and 20 
(24%) of them showed a fourfold or greater rise in 
antibody titers to EBV VCA. Of these patients, only 
one patient had symptomatic EBV infection mani-
fested by lymphoproliferative disease 143 dafter 
transplantation. The patient had enlarged periaor-
tic lymph nodes with no evidence of disease outside 
the abdomen. EBV DNA was found in these nodes 
by nucleic acid hybridization. He was treated with 
radiation therapy along with reduction in his im-
munosuppression, and the disease eventually re-
gressed. 
Only two patients in the study population were 
seronegative for EBV preoperatively. They serocon-
verted on day 30 and 72, respectively, after transplan-
tation and had no disease attributable to EBV, al-
though one patient had concomitant CMV infection. 
Table 4. Immunosuppression in recipients seropositive for HSV and frequency of symptomatic HSV infection. 
No. of patients with 
Total no. of 
Additional Total no. Genital Other HSV symptomatic 
immunosuppression of patients Oral HSV HSV infections patients 
None 0 0 0 0 
AZA only 5 2 0 0 2 
Steroids only 35 7 I 11 
OKT3* 54 20 7 3 29t 
Total 95 29 10 4 42 
* All patients treated with OKT3 received additional steroids; 32 of 54 OKT3-treated patients also received AZA (azathioprine). 
t p = .05 for OKT3-treated patients with symptomatic HSV (29 of 54) vs. symptomatic patients (13 of 41) who did not receive 
OKT3. One patient had both oral and genital HSV and is counted only once. 
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Herpesvirllses and Liver Transplantation 
Nine (45070) of 20 patients with reactivation EBV 
infection had symptomatic CMV infection as com-
pared with 17 (26070) of 65 without EBV reactiva-
tion. This difference was not statistically significant. 
VZV infections. Eight (7070) of the 121 patients 
developed clinical VZV infection. Seven patients had 
localized dermatomal zoster that developed a me-
dian of 167 d afrer transplantation (range, 19-575 d). 
One patient developed fulminant varicella with vis-
ceral involvement 32 d after transplantation and died 
despite treatment with acyclovir. 
Discussion 
This study is the first to characterize the frequency 
and morbidity of viral infections in a large group 
of adult liver transplant recipients and expands upon 
our previous studies in this population [8]. CMV re-
mains the most important viral pathogen occurring 
after transplantation. Of 93 assessable patients, 55 
(59070) developed CMV infection after transplanta-
tion. These results are similar to those reported in 
renal transplant patients but somewhat lower than 
those reported in cardiac transplant recipients [16]. 
An association of symptomatic CMV disease with 
primary CMV infection has been shown for 
recipients of kidney and heart allografts [3, 15]. Our 
results show both an increased incidence of symp-
tomatic CMV infection and a higher frequency of 
disseminated disease in liver transplant recipients 
with primary CMV infection. Whelchel et al. [17] 
have reported a higher mortality rate in renal trans-
plant recipients with symptomatic CMV infection. 
In our study, the mortality of patients with symp-
tomatic disease (18070) did not differ significantly 
from the mortality of patients with asymptomatic 
CMV infection (25070). Disseminated CMV infection 
was associated with a significantly higher mortality 
than was nondisseminated CMV infection. However, 
all four patients with disseminated CMV who died 
had concomitant systemic bacterial or fungal infec-
tions, and their deaths were probably due to multi-
ple factors. 
Two important possible sources of CMV acquisi-
tion in transplant patients are organ allograft and 
blood products. Our data show that the hepatic al-
lograft is an important source of CMVinfection in 
seronegative liver recipients. Seronegative recipients 
who received livers from seropositive donors had an 
infection rate of 92070 (13 of 14). This finding is con-
sistent with similar serological evidence that other 
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major organ transplantation is associated with trans-
mission of CMV [11, 15, 18]. Such evidence has now 
been further strengthened by proving the identity of 
donor strains of CMV in renal recipients by en-
donuclease restriction patterns [19]. In an earlier 
study we calculated that in the Pittsburgh area, the 
risk of acquiring CMV infection from transfused 
units of blood, on the basis of data from seronega-
tive pediatric patients undergoing open heart sur-
gery, was 2.7070 per unit [20]. Hence, the risk of CMV 
infection was low in operations in which usually <10 
units were required [21]. However, even in the case 
of liver transplantation in which significantly more 
than 10 units of blood and other blood products are 
used [22], we have not been able to demonstrate an 
association between primary infection and units of 
blood used, either in pediatric liver recipients [9] or 
in adults. 
A noteworthy finding in our study is the impact 
of OKT3 antibodies on CMV infection. OKT3 ap-
peared to increase the risk of dissemination in pa-
tients with primary CMV infection. Different im-
munosuppressive agents may have different effects 
on CMV infection. Corticosteroids alone appear to 
have little effect on CMV infection, whereas cyto-
toxic immunosuppressants such as AZA do have the 
ability to reactivate latent virus [23]. Since the in-
troduction of CsA into clinical organ transplanta-
tion, numerous studies have documented a lower in-
cidence of symptomatic CMV infection in patients 
treated with CsA [28, 29]. Comparing CMV infec-
tion and disease in renal transplant patients receiv-
ing either AZA or CsA, but not ATG, we and Bia 
et al. were unable to show a difference [7,26]. Rubin 
et al. [27] have concluded that adding agents such 
as ATG is more important in potentiating CMV dis-
ease than is the basic immunosuppressive regimen. 
Their conclusions are based. on studies that report 
an increased incidence of symptomatic CMV infec-
tion in renal transplant recipients receiving conven-
tional regimens of AZA, prednisone, and ATG, com-
pared with renal transplant patients receiving CsA 
and prednisone alone [28, 29]. The incidence of 
symptomatic CMV infection in patients receiving 
AZA and prednisone without ATG, however, appears 
to be similar to the rate of symptomatic CMV infec-
tion in renal transplant recipients receiving CsA and 
prednisone [26]. Peterson et ai. [30] compared the 
incidence of CMV pneumonia in a group of renal 
transplant patients receiving these two regimens and 
postulated that the higher incidence of CMV pneu-
130 
monia in the group receiving ATG, prednisone, and 
AZA was related to the use of ATG. Therefore, we 
believe that the ability to potentiate CMV infections 
is not unique to OKT3 but that it shares this charac-
teristic with other antilymphocyte preparations. 
However, because OKT3 was used to treat severe epi-
sodes, it may well be that the higher incidence of dis-
seminated CMV infection in these patients was due 
to a combination of factors such as severe graft re-
jection along with concomitant bacterial and fun-
gal infections that may have increased their net state 
of immunosuppression. 
As reported in other organ allograft recipients [31], 
HSV infections were mostly due to reactivation of 
latent virus. Forty-four percent (42 of 95) of seroposi-
tive patients in our study developed symptomatic 
HSV infection. Of great interest was the case of pri-
mary HSV infection (HSV hepatitis) in this study, 
with a histopathologically documented cure after 
acyclovir treatment. To our knowledge this is the first 
reported case of primary HSV hepatitis cured with 
acyclovir in a transplant recipient. The patient pos-
sibly acquired HSV infection from the donor. We 
have documented probable transmission of HSV in-
fection by the donor organ in kidney recipients, but 
this route is rare and has not been documented for 
liver recipients [35, 36]. 
A few studies have correlated the use of antilym-
phocyte preparations with an increased risk of reac-
tivation and symptomatic illness due to HSV [32]. 
Preiksaitis [33] studied heart transplant recipients 
at Stanford Univeristy (Stanford, Calif) and reported 
significantly more symptomatic and severe illness 
due to recurrent herpes labialis in patients treated 
with high-dose ATG. Similar data are not available 
for OKT3, but we observed a trend toward a higher 
frequency of symptomatic HSV infections in 
seropositive patients treated with OKT3. Most of 
these infections were mucocutaneous and, therefore, 
not life-threatening. Because this is a retrospective 
study, a number of these patients did not have cul-
tures of the lesions performed or were already being 
treated with acyclovir when cultures were performed. 
It is our experience in a large transplant population, 
however, that cultures of typical oral or genital le-
sions for herpes are almost invariably positive if ob-
tained before antiviral therapy. The number of pa-
tients with visceral HSV infections in our study was 
too small to assess if OKT3 increased the risk of 
visceral or disseminated HSV. Physicians caring for 
liver transplant recipients should be aware that 
Singh et af. 
visceral HSV infections (particularly hepatitis) may 
occur in some of their patients. Liver biopsies ap-
pear to be diagnostically useful in this setting. 
VZV infection was seen in 7OJo (eight of 121) of 
our patients. Seven patients had localized zoster. One 
patient with primary varicella died rapidly of dis-
seminated visceral disease. It is well known that 
varicella has a high morbidity and mortality rate in 
transplant recipients [34]. Because hyperimmune 
globulin against VZV (VZIG) may prevent or ame-
liorate this illness, it is probably prudent to monitor 
transplant candidates with no history of chickenpox 
for VZV antibody t<Adetermine their susceptibility 
to infection. The number of patients with herpes zos-
ter was too small to measure the effect of OKT3 on 
reactivation. 
We found an EBV reactivation infection rate of 
24%, which is similar to what was previously 
reported [12]. In our patients we could not definitely 
attribute any viral syndrome to EBV, possibly be-
cause of simultaneous evidence of CMV infection. 
One seropositive patient, however, developed an 
atypical EBV-related lymphoma. 
In summary, 65 (53%) of 121 adult liver transplant 
recipients had one or more symptomatic infections 
with herpesviruses. Although effective therapy for 
HSV and VZV infection exists, some cases may still 
be fatal. CMV infection continues to be a major 
problem in liver transplant recipients, and active re-
search into the diagnosis, prevention; and therapy 
of these infections is still needed. 
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